Next Article in Journal
Direct Evidence of Powassan Virus Vertical Transmission in Ixodes scapularis in Nature
Previous Article in Journal
Clinical Manifestations of Infections with the Omicron Sub-Lineages BA.1, BA.2, and BA.5: A Retrospective Follow-Up Analysis of Public Health Data from Mecklenburg-Western Pomerania, Germany
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 16
Issue 3
10.3390/v16030455
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review

by
Evanthia Thomaidou
1,
Eleni Karlafti
2,3,
Matthaios Didagelos
1,4,
Kalliopi Megari
5,
Eleni Argiriadou
1,
Karolina Akinosoglou
6,
Daniel Paramythiotis
7 and
Christos Savopoulos
3,*
1
Department of Anesthesiology and Intensive Care Unit, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
2
Emergency Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
3
First Propaedeutic Internal Medicine Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
4
1st Cardiology Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
5
CITY College, University of York Europe Campus, 54626 Thessaloniki, Greece
6
Department of Medicine, University General Hospital of Patras, 26504 Rio, Greece
7
First Propaedeutic Department of Surgery, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
Viruses 2024, 16(3), 455; https://doi.org/10.3390/v16030455
Submission received: 12 February 2024 / Revised: 11 March 2024 / Accepted: 13 March 2024 / Published: 15 March 2024
(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
Versions Notes

Abstract

:
Acute acalculous cholecystitis (AAC) represents cholecystitis without gallstones, occurring in approximately 5–10% of all cases of acute cholecystitis in adults. Several risk factors have been recognized, while infectious diseases can be a cause of cholecystitis in otherwise healthy people. Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has spread worldwide, leading to an unprecedented pandemic. The virus enters cells through the binding of the spike protein to angiotensin-converting enzyme 2 (ACE2) receptors expressed in many human tissues, including the epithelial cells of the gastrointestinal (GI) tract, and this explains the symptoms emanating from the digestive system. Acute cholecystitis has been reported in patients with COVID-19. The purpose of this review is to provide a detailed analysis of the current literature on the pathogenesis, diagnosis, management, and outcomes of AAC in patients with COVID-19.

1. Introduction

Acute acalculous cholecystitis (AAC) was first described by Duncan in 1884 and represents cholecystitis without gallstones, being present in approximately 5–10% of all cases of acute cholecystitis in adults [1,2,3,4]. AAC occurs more frequently in critically ill patients, and risk factors include trauma, surgery, shock, burns, sepsis, total parenteral nutrition (TPN), and mechanical ventilation [3]. Unfortunately, it is associated with a high mortality rate of approximately 30%, not only because the disease itself is severe but also because it can be complicated by necrosis, perforation, and empyema with a higher incidence than calculous cholecystitis [3]. AAC can also appear in healthy people, mainly due to infectious causes [2,4].
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was first reported in December 2019 in Wuhan, China. It spread worldwide, leading to a devastating pandemic with more than 300 million cases and more than 5 million deaths reported worldwide in 3 years [5,6]. The virus invades cells through the binding of the SARS-CoV-2 spike protein to angiotensin-converting enzyme 2 (ACE2) receptors expressed on the host cell surface. ACE2 receptors are expressed in many human tissues, with the highest expression levels being found in the alveolar cells of the lungs and the epithelial cells of the gastrointestinal (GI) tract, explaining the respiratory and gastrointestinal symptoms of the disease [7].
The purpose of this review is to provide a detailed analysis of the current literature on the pathogenesis, diagnosis, management, and outcomes of AAC in patients with COVID-19. An international literature search was carried out via MEDLINE/PubMed, Scopus, the Cohrane Library, and Google Scholar using the keywords “acute acalculous cholecystitis” and “COVID-19”. After title and abstract screening, all manuscripts describing at least one case of AAC in COVID-19 patients were further analyzed, and after duplicate removal, all cases were included in this review.

2. Gastrointestinal Manifestations and Complications of COVID-19 Infection

Angiotensin-converting enzyme 2 (ACE2) receptors are largely expressed in the gastrointestinal (GI) tract, making it prone to direct damage from the cellular invasion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many GI symptoms have been described in patients with COVID-19 disease, with their incidence ranging from 2% to 79.1%. The most common symptoms include anorexia (26.8%), diarrhea (7.4–12.5%), nausea/vomiting (4.6–10.2%), and abdominal pain/discomfort (9.2%) [8,9,10,11,12,13]. More severe complications like ileus and life-threatening mesenteric ischemia arise in 74% to 86% of critically ill patients during lengthy hospitalization [14,15,16]. Certain GI illnesses (Inflammatory Bowel Disease, Chronic Liver Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, and GI malignancies) predispose for severe COVID-19 infection, while proton pump inhibitor (PPI) and glucocorticoid use have been associated with severe clinical outcomes in COVID-19 infection [8,17,18].

3. Biliary Manifestations of COVID-19

Acute cholecystitis has been reported in patients with COVID-19, primarily in those who are critically ill. Most cases are AAC, which occurs due to a reduction in the mobility of the gallbladder and occurs in patients with severe illness, infection, and mechanical ventilation [8]. Because of the widespread expression of ACE2 in the liver, gallbladder, and bile ducts, the virus may play a major role in the development of cholecystitis through direct invasion and replication in the gallbladder and bile ducts. The detection of viral RNA in the bile wall and gallbladder further supports this hypothesis. Other possible mechanisms include inflammation due to cytokine release syndrome, ischemia due to hypercoagulability, and thrombotic microangiopathy due to SARS-CoV-2 infection [19,20,21,22,23]. However, all the aforementioned findings are just hypotheses of a possible relationship between COVID-19 and AAC, since there are no large studies with robust data supporting a definite causal relationship between these two pathologies.

4. Types of AAC

Pathologically, four types of AAC are described [1]:
  • Simple cholecystitis (inflammation of the gallbladder with no other complications).
  • Acute suppurative cholecystitis (cholecystitis complicated by the presence of pus in the gallbladder lumen).
  • Gangrene cholecystitis (cholecystitis complicated by gallbladder wall necrosis).
  • Gallbladder perforation (cholecystitis complicated by gallbladder wall rupture).
Aetiologically, the inflammation occurring in ACC can be due to the following causes [1]:
  • Mechanical causes (due to increased pressure in the gallbladder lumen resulting in the compression and ischemia of its wall and mucosa).
  • Chemical causes (phospholipases act on the lecithin of bile, producing hemolytic lecithin, resulting in chemical inflammation).
  • Bacterial causes (presence of microorganisms in the gallbladder).

5. AAC Pathogenesis

AAC development involves an interplay between several pathological processes. When AAC is associated with infectious agents, its pathogenesis can be divided into two categories: (1) AAC in critically ill patients and (2) AAC in patients with a non-critical illness [2].

5.1. AAC in Critically Ill Patients

5.1.1. Bile Stasis

Bile stasis plays a crucial role in the pathogenesis of AAC in critically ill patients. This can be induced by TPN and prolonged fasting, volume depletion, opioid analgesics, hormones, and certain drugs that impair either the viscosity or the mobility of the gallbladder smooth muscle, causing cholestasis [24,25,26,27,28,29,30]. Additionally, a modified lipid metabolism in type II diabetes and cerebrovascular disease and mechanical ventilation with positive end-expiratory pressure (PEEP) > 7 cm H2O also lead to cholestasis [31,32]. Bile stasis causes direct injury to the gallbladder mucosa due to changes in the bile’s chemical composition (e.g., lysophosphatidylcholine) [33].

5.1.2. Gallbladder Ischemia–Reperfusion Injury

The gallbladder is mainly supplied by the cystic artery, a terminal artery, so it is vulnerable to ischemia. Tissue hypoxia may be caused by septic shock, hypovolemic shock, trauma, burns, and cardiovascular surgeries. Objective evidence of the role of ischemia in AAC has been provided by microangiography showing a poor and irregular capillary network in AAC, in contrast with acute calculous cholecystitis (ACC), where a dense vessel network and dilated arterioles are depicted [31,34,35,36,37,38].

5.2. AAC in Non-Critically Ill Patients

5.2.1. Direct Invasion

Several microorganisms can infiltrate the gallbladder’s epithelium and initiate an inflammatory process. They are usually identified by a combination of the histopathology of the gallbladder wall, molecular techniques, electron micrographs, and bile cultures. The overuse of opioids during GI surgeries, as well as the sphincter of Oddi being subjected injury and spasming, can lead to infection. Moreover, invasive procedures like endoscopic retrograde cholangiopancreatography (ERCP) have a risk of bacterial infection. Sepsis and systemic infection can also induce AAC by gallbladder bacterial colonization through blood circulation. Additionally, infections of the surrounding organs can transmit bacteria directly into the gallbladder [24,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62].

5.2.2. Vasculitis

Vasculitis is another mechanism that causes gallbladder injury by inducing local ischemia and, subsequently, cell death and gallbladder necrosis. Several viruses have been reported to affect the gallbladder through immune-mediated necrotizing vasculitis. Antibody dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity are considered possible mechanisms, while others [63,64,65,66] have stated that AAC can be caused by the destruction of the endothelium, causing the extravasation of fluid and leading to gallbladder wall edema or nonocclusive thrombosis [67,68].

5.2.3. Obstruction

The biliary tract may be obstructed by intrinsic or extrinsic factors, leading to different degrees of obstruction and, subsequently, AAC. Increased intraluminal pressure and increased gallbladder wall tension lead to ischemia and AAC [69,70,71]. Extrinsic compression and the obstruction of the biliary tree may arise from the formation of hydatid cysts during the course of echinococciasis or from portal lymphadenitis during the course of infectious diseases like Epstein–Barr virus (EBV) disease [72,73].

5.2.4. Anatomical Abnormalities of the Biliary Tract System

Congenital abnormalities of the biliary system, for example, biliary cysts, torsion of the gallbladder, enlarged gallbladder neck, duct diameter narrowing, or a completely intrahepatic gallbladder, may impair the ability to empty the bile ducts. This leads to cholestasis, followed by an increased risk of AAC [57,74,75,76,77].

5.2.5. Other Risk Factors

Other risk factors that increase the risk of AAC are immunodeficiencies, atherosclerosis, vasculitis, diabetes mellitus, stroke, arterial hypertension, factors reducing vagal tone, bone marrow transplantation, interleukin-2 therapy, and lymphokine-activated killer cell therapy [35,78,79,80,81,82,83].

5.2.6. Sequestration

Sequestration explains the pathogenesis of ACC in malaria infections and especially during Plasmodium falciparum infection. Infected erythrocytes lose their normal shape due to the appearance of protrusions (knobs) on their surface. This deformation causes erythrocyte cells to adhere to each other and to the vessel walls, resulting in microcirculatory obstruction and ischemia [84,85,86,87].

5.2.7. Epstein–Barr Virus (EBV)

EBV has been reported as the most frequent infectious cause of AAC. The exact pathophysiological mechanism remains unclear, with the direct invasion of the gallbladder’s epithelial cells, vasculitis, and the extrinsic blockage of the cystic duct by inflamed and enlarged lymph nodes all having been proposed. It is a fact, however, that even after cholecystectomy and the in situ hybridization of the removed tissue, the virus may not be revealed [40,73,87,88,89].

6. AAC Pathogenesis in COVID-19

The pathogenesis of AAC during COVID-19 infection still remains vastly unknown. Critical illness, mechanical ventilation, and prolonged total parenteral nutrition (TPN) are considered the usual triggers. SARS-CoV-2 enters cells through the angiotensin-converting enzyme 2 (ACE2) receptors. Because ACE2 receptors are highly expressed in the biliary tree and the vascular endothelium of the gallbladder, the direct invasion of these structures is considered a possible pathophysiological mechanism. Alternatively, SARS-CoV-2 can infect small intestinal enterocytes which express ACE 2 receptors and enter the gallbladder through the bile recirculation process. It can also be supposed that the virus may spread to extrapulmonary organs including the gallbladder and give typical clinical manifestations [21,90,91,92]. It should be noted, however, that in most cases, the virus has not been detected locally in the bile or tissue samples of affected patients, except for in two cases [19,93].
A few theories trying to explain possible connections between SARS-CoV-2 and AAC have been defined. One such theory considers that the alterations to the immune system due to the SARS-CoV-2, the systemic inflammation that follows, and the subsequent treatment applied activates proinflammatory pathways that cause late-onset cholecystitis [94]. Moreover, the coagulopathy and prothrombotic state caused by the coronavirus can cause small-vessel thrombosis and gallbladder wall ischemia [95,96,97,98]. Furthermore, SARS-CoV-2 can directly affect the gallbladder’s epithelial cells because of the high expression of ACE2 receptors among them [99]. In a study by Bozada-Gutiérrez et al., a histopathological examination showed ischemia and necrosis (because of thrombosis in the small vessel), hemorrhagic changes, and acute inflammatory infiltrates in the gallbladder wall, accompanied by acute peritonitis [100].

7. Worldwide Cases of AAC in COVID-19

Several reports in the literature have described the presentation of acute cholecystitis in COVID-19 patients, with most of them being case reports and letters to the editor and some case series (Table 1) [10,19,20,21,22,91,92,94,95,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114].
Bruni et al., described the first case of histopathological findings of an acute ischemic gangrenous cholecystitis as a late complication in a COVID-19 [95].
Several other cases pointed out the presence of gangrenous AAC [21,91,101]. In a cohort study by Bozada et al., all patients had cholelithiasis except for one with AAC [100]. Different pathophysiological mechanisms, all of which would need further analysis, could be hypothesized here. However, all patients required cholecystectomy, irrespective of the aetiology of the cholecystitis. In the ChoCO-W prospective observational global study, there was no difference in AAC between non-COVID and COVID patients (3.9% vs. 4.6%, p = 0.18); cholecystitis with necrosis/gangrene was more common in the COVID group (40.7% vs. 22.3%), and mortality was higher in the COVID group (13.4% vs. 1.7%) [110].
Cirillo et al. [102] presented a case of acalculous hemorrhagic cholecystitis in a COVID-19 patient that required an emergency cholecystectomy. However, this is a very rare finding, and establishing an association with COVID-19 would require larger studies.
Regarding acute cholecystitis management, antibiotics [117], percutaneous cholecystostomy [118,119], and laparoscopic or open cholecystectomy [117,120] have been applied. When medical treatment with antibiotics only or cholecystostomy are considered insufficient, urgent cholecystectomy is indicated [101,121,122] (Table 1).

8. Diagnosis of ACC in COVID-19

8.1. Signs and Symptoms

AAC usually presents with a fever of unknown origin and persistent or intermittent right upper abdominal pain, together with other nonspecific signs of GI disease, like nausea, vomiting, and jaundice. When complicated by gallbladder perforation, right epigastric tenderness, a positive Murphy’s sign, a palpable right epigastric mass, and peritoneal irritation usually arise. All these symptoms and signs cannot be evaluated in critically ill intubated patients, and this is one of the reasons for delayed diagnoses in such circumstances [123].

8.2. Laboratory Investigations

Several laboratory abnormalities occur in AAC; however, they are nonspecific for the disease and should be carefully taken into account and evaluated in the context of the other clinical and imaging findings. Such abnormalities include higher than normal levels of white blood cells, neutrophils, and C-reactive protein; an increase in aminotransferase; mild-to-moderate bilirubin elevation, small blood amylase elevation, and positive blood cultures [123].

8.3. Imaging

Imaging plays a crucial role in AAC diagnosis, taking into account the predisposing factors, clinical situation, and laboratory findings.
B-scan ultrasound examination of the upper abdomen is usually the first-line modality, since it is simple, inexpensive, easy to perform (even at bedside), widely available, and effective (specificity 30–100%, sensitivity 30–100%), with no obvious contraindications. The diagnostic criteria for AAC are as follows: (1) positive Murphy’s sign upon ultrasound, (2) no gallbladder stones, (3) gallbladder dilatation (longitudinal diameter ≥ 8 cm and transverse diameter ≥ 5 cm), (4) gallbladder wall thickening (gallbladder wall ≥ 3.5 mm, depicted as “bilateral” or “double-walled” sign), (5) peritoneal effusion and biliary-type gallbladder drainage, (6) echoes occurring in the gallbladder cavity or wall, and (7) bile (bile sludge may be present) [124].
CT scan of the abdomen is the second most frequently used modality, typically deployed when an ultrasound cannot reach a definite conclusion or to confirm the findings of the ultrasound. When both are used, sensitivity and specificity significantly increases. The diagnostic criteria for the CT scan are as follows: (1) no stones in the gallbladder neck or cystic duct and thickened (≥0.3 cm) and enhancing wall; (2) pericholecystic fat stranding with or without pericholecystic fluid and reactive enhancement in the adjacent liver; (3) in cases of gangrenous cholecystitis, nonenhancing wall, sloughed membranes, mural striation, irregular enhancing wall with defect and pericholecystic fat stranding and fluid are noted; (4) when the gallbladder is perforated, focal defect in the gallbladder wall accompanied by pericholecystic fluid or hepatic abscesses [125,126,127].
Magnetic resonance cholangiopancreatography (MRCP) is another non-invasive imaging option. This is a simple and safe exam that depicts the bile pancreatic duct system. It can also provide 3D and multiangle images of the biliary tract system to detect anatomical abnormalities. However, it is more expensive, complicated, and not widely available, so its use in clinical practice remains limited [128].
Endoscopic retrograde cholangiopancreatography (ERCP) is an invasive method that provides direct imaging of the biliary tree and also the possibility to act therapeutically. However, it is more associated with pancreatitis and has limitations in anatomical abnormalities of the biliary tract, so it also not frequently used [1].
Another, more sophisticated, imaging technique is hepatobiliary dynamic imaging (HIDA). In HIDA, hepatic bilirubin distribution is stimulated by the intravenous injection of acetanilide iminodiacetic acid compounds radiolabeled by imaging agent 99 m TC-EHIDA. The imaging agent is absorbed by liver cells, secreted into bile, and then excreted into the intestinal tract, and it can be observed through a flashing dynamic imaging camera to understand the morphological and functional structure of the liver and gallbladder. The test can take hours to reach a final conclusion; it is not useful for seriously ill patients and is not widely available, so its use is very limited [129].

8.4. Pathology

AAC, unlike calculous cholecystitis, is usually complicated by necrosis of the gallbladder tissue because of blood circulation disorder and blood stasis. Histopathology reveals a degenerated and necrotic mucosal epithelium of the gallbladder, the formation of multiple erosive ulcers, and infiltration by many neutrophils and other inflammatory cells [130].

9. Differential Diagnosis of AAC in COVID-19

Diagnosing AAC is difficult, and clinical findings may be misleading sometimes, especially in critically ill patients and in patients with many other comorbidities. The main conditions that are involved in the differential diagnosis of AAC and may mimic its clinical manifestations are other gastrointestinal pathologies like cholangitis, pancreatitis, hepatitis, sepsis with biliary tract infection, acquired immunodeficiency syndrome (AIDS), cholangiopathy, total parenteral nutrition (TPN), alcohol-associated liver disease, ischemic bowel disease, bowel perforation, renal pathologies like nephrolithiasis, and cardiovascular disease (CVD) [131,132,133].
Clinically, in COVID-19 patients, making a clear distinction between acute acalculous cholecystitis and acute calculous cholecystitis is very difficult because the symptoms are similar and only imaging (ultrasound or CT) can help differentiate between the two conditions. As reported by the ChoCo-W, even in COVID-19 patients, gallstone cholecystitis was more frequent, with no difference in symptoms between AAC and ACC.
Especially for CVD, AAC may present like angina, myocarditis/pericarditis, and myocardial infarction with elevated troponin levels and ECG changes (T wave inversion, ST segment elevation, or depression), probably due to coronary vasospasms induced by a vagally mediated reflex or by decreased coronary blood flow due to distention of the common bile duct [131,132,133].
Imaging methods that can be combined with abdominal ultrasound and abdominal CT scan are usually the modalities that will differentiate between AAC and most of the other gastrointestinal or renal pathologies. As CVD is measured via serial troponin measurements (to record its kinetics), serial ECGs (to monitor T wave and ST segments changes), echocardiography (to exclude segmental myocardial wall motion abnormalities and pericardial effusion), and coronary angiography in very high-risk patients for CVD will be needed when AAC diagnosis remains vague after the aforementioned exams in order to identify early cardiovascular pathology [131,132,133].
For critically ill patients, the use of diagnostic laparoscopy and laparotomy when AAC cannot be excluded by non-invasive methods is also recommended.

10. Treatment of AAC in COVID-19

The severity of AAC and subsequent treatment are largely based on the 2018 Tokyo Guidelines, which take into account predisposing factors; the Charlson Comorbidity Index score; and the American Society of Anesthesiologists-physical status score [134]. There are three levels of severity, ranging from I to III, with III being the most serious. Grade III (severe) AAC is associated with organ or systemic dysfunction, including cardiovascular dysfunction, neurological dysfunction, respiratory dysfunction (PaO2/FiO2 ratio < 300), kidney dysfunction (oliguria or creatinine > 2.0 mg/dL), hepatic dysfunction (PT-INR > 1.5), and hematological dysfunction (platelet count < 100,000/mm3). Grade II (moderate) AAC involves an elevated WBC count (>18,000/mm3), palpable tender mass in the right upper abdominal quadrant, duration of symptoms > 72 h, and marked local inflammation (gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, and emphysematous cholecystitis). Grade I (mild) AAC is defined as acute cholecystitis in an otherwise healthy patient with no organ dysfunction and mild inflammatory changes in the gallbladder [121].
Mild AAC in the early stage is managed conservatively. After nonsurgical treatment, the recurrence rate is lower in AAC than in ACC (2.7 vs. 23.2%). Severe AAC requires surgical treatment. The incidence of gangrenous cholecystitis is higher in AAC [135,136,137]. In contrast early surgical treatment is recommended for patients with ACC.
In AAC, the mortality rate after surgery in non-COVID-19 patients is 9–75%, higher than that for calculous cholecystitis. However, this also depends on the severity of the underlying disease and is usually higher when there are systematic organ lesions rather than just hepatobiliary complications [138,139].

10.1. Conservative Treatment

Conservative treatment is initially applied in mild stages of AAC in early-diagnosed patients who are in a good general condition. Conservative measures include fasting, gastrointestinal decompression, antibiotics, electrolyte and acid-base homeostasis, symptomatic support treatment, and primary disease management [136]. In order to select the most appropriate antibiotic regimen, it is crucial to carefully take into account all laboratory markers, vital signs, and overall condition. Biliary tract infections are usually caused by Gram-negative bacteria and third-generation cephalosporins, and aminoglycosides are more often used. If conservative treatment is deemed unsuccessful in controlling the inflammation, surgical treatment is the next step to diminish the risk of gallbladder necrosis and perforation.

10.2. Cholecystectomy

Cholecystectomy, whether laparoscopic, open, or partial cholecystectomy, is the preferred treatment for AAC, minimizing trauma. According to the 2018 Tokyo Guidelines, the surgical technique should be individualized based on the surgical risk. Laparoscopy offers safety benefits like less painful incision sites, shorter hospital stays, shorter recovery periods, and improved quality of life [134].

10.3. Drainage

For critically ill patients unable to tolerate anesthesia and surgery, ultrasound-guided percutaneous cholecystostomy (PC) is a good alternative. During this procedure, called percutaneous transhepatic gallbladder drainage (PTGD), a PC catheter is placed in the gallbladder through the liver and the abdomen. PTGD is generally the first choice in clinical practice [140,141,142]. The advantages of PTGD are as follows: (1) it relieves the pressure in the gallbladder immediately, resulting in a decline in inflammation; (2) it is less traumatic and has fewer anesthetic complications compared to surgery; (3) the operation time is short, meaning that the recovery time is also short, and there are few postoperative complications; and (4) it can be used as the only treatment.
Especially for elderly patients, PTGD is also a safe and effective treatment method with proven efficacy and few complications [140]. After placing the PC tube, the color, drainage, and bile characteristics should be checked regularly to avoid the prolapse and contortion of the PC tube and to evaluate liver function, focusing on the presence of cholestasis. However, there is still a debate regarding the optimal timing of PC tube removal (at 4 or 7 days) [135,143].
A new and effective alternative gallbladder drainage procedure in AAC patients is also endoscopic transpapillary gallbladder drainage under ERCP (involving endoscopic naso-gallbladder drainage and gallbladder stenting [EGBS] and endoscopic ultrasound-guided gallbladder drainage [EUS-GBD]) [144]. During this procedure, a lumen-apposing metal stent (LAMS) is placed between the duodenal bulb or the gastric antrum and the gallbladder during an endoscopic ultrasound. The two sides of the stent are fixed to the gastrointestinal tract and the gallbladder, respectively, to establish a safe passage for internal drainage. This method can be applied in cases of gallbladder enlargement that are difficult to manage with direct surgical resection and in cases with an increased risk for duodenal or gastric perforation. It can also be applied as a form of palliative care for patients at an extreme or very high risk of surgery or those who have a short life expectancy [143,144,145,146,147].

11. Outcomes of AAC in COVID-19

As seen in Table 1, most cases of AAC in COVID patients were managed successfully and recovered. Death usually occurred in high-risk or critically ill patients or when complications occurred. However, in the ChoCO-W prospective observational global study (acute cholecystitis comparison between 180 COVID and 2412 non-COVID patients), mortality was higher in the COVID group (13.4% vs. 1.7%) [110]. When distinguishing between non-ICU-associated COVID-19 AAC (non-ICU–AAC) and ICU-associated COVID-19 AAC (ICU-AAC), we can observe that most cases were non-ICU AAC (n = 29) rather than ICU-AAC (n = 19), with four deaths versus seven deaths, respectively (excluding the ChoCo-W registry that included acute cholecystitis in general). Based on these reports, if we could just try to provide an impression (no definite evidence at all) about mortality, it looks like the mortality rate is lower in non-ICU-AAC patients (13.8%) versus ICU-AAC patients (36.8%). ICU-AAC onset was usually after a long stay in the ICU including mechanical ventilation, increasing the vulnerability of these patients and leading to an increased mortality rate.

12. Conclusions

AAC could be considered a possible complication of COVID-19 disease, especially in patients with concomitant comorbidities or other risk factors for AAC. The pathogenesis of AAC in COVID-19 has not been fully elucidated, and more evidence is needed to understand the effect of SARS-CoV-2 on the hepato-biliary system. Initial conservative management followed by percutaneous cholecystostomy when it fails looks to be the most feasible option during AAC cases with COVID-19. Cholecystectomies, laparoscopic or open, are reserved in case of complications (perforation, gangrene). Although the outcomes are usually favorable, especially in non-critically ill patients, morbidity and mortality are increased in critically ill patients and when AAC is complicated by gangrene and/or perforation.

Author Contributions

Conceptualization, E.T.; methodology, E.T. and M.D.; software, M.D.; validation, K.M., E.T., E.A. and E.K.; formal analysis, E.T.; investigation, E.T. and M.D.; resources, E.T. and M.D.; data curation, D.P.; writing—original draft preparation, E.T. and M.D.; writing—review and editing, all authors; visualization, E.T. and M.D.; supervision, E.A., K.A., D.P. and C.S.; project administration, E.A., K.A., D.P. and C.S.; All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Fu, Y.; Pang, L.; Dai, W.; Wu, S.; Kong, J. Advances in the Study of Acute Acalculous Cholecystitis: A Comprehensive Review. Dig. Dis. 2022, 40, 468–478. [Google Scholar] [CrossRef]
  2. Markaki, I.; Konsoula, A.; Markaki, L.; Spernovasilis, N.; Papadakis, M. Acute acalculous cholecystitis due to infectious causes. World J. Clin. Cases 2021, 9, 6674–6685. [Google Scholar] [CrossRef]
  3. Huffman, J.L.; Schenker, S. Acute acalculous cholecystitis: A review. Clin. Gastroenterol. Hepatol. 2010, 8, 15–22. [Google Scholar] [CrossRef]
  4. Poddighe, D.; Sazonov, V. Acute acalculous cholecystitis in children. World J. Gastroenterol. 2018, 24, 4870–4879. [Google Scholar] [CrossRef]
  5. Liu, Y.C.; Kuo, R.L.; Shih, S.R. COVID-19: The first documented coronavirus pandemic in history. Biomed. J. 2020, 43, 328–333. [Google Scholar] [CrossRef]
  6. WHO Coronavirus (COVID-19) Dashboard. 2022. Available online: https://covid19.who.int/ (accessed on 8 March 2022).
  7. Bourgonje, A.R.; Abdulle, A.E.; Timens, W.; Hillebrands, J.L.; Navis, G.J.; Gordijn, S.J.; Bolling, M.C.; Dijkstra, G.; Voors, A.A.; Osterhaus, A.D.; et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J. Pathol. 2020, 251, 228–248. [Google Scholar] [CrossRef]
  8. Ghazanfar, H.; Kandhi, S.; Shin, D.; Muthumanickam, A.; Gurjar, H.; Qureshi, Z.A.; Shaban, M.; Farag, M.; Haider, A.; Budhathoki, P.; et al. Impact of COVID-19 on the Gastrointestinal Tract: A Clinical Review. Cureus 2022, 14, e23333. [Google Scholar] [CrossRef]
  9. Gebran, A.; Dorken-Gallastegi, A.; Kaafarani, H.M.A. A Surgical Perspective of Gastrointestinal Manifestations and Complications of COVID-19 Infection. Gastroenterol. Clin. N. Am. 2023, 52, 49–58. [Google Scholar] [CrossRef]
  10. Dong, Z.Y.; Xiang, B.J.; Jiang, M.; Sun, M.J.; Dai, C. The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 infection: A systematic review and meta-analysis. J. Clin. Gastroenterol. 2021, 55, 67–76. [Google Scholar] [CrossRef]
  11. Cheung, K.S.; Hung, I.F.N.; Chan, P.P.Y.; Lung, K.C.; Tso, E.; Liu, R.; Ng, Y.Y.; Chu, M.Y.; Chung, T.W.H.; Tam, A.R.; et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis. Gastroenterology 2020, 159, 81–95. [Google Scholar] [CrossRef]
  12. Hunt, R.H.; East, J.E.; Lanas, A.; Malfertheiner, P.; Satsangi, J.; Scarpignato, C.; Webb, G.J. COVID-19 and gastrointestinal disease: Implications for the gastroenterologist. Dig. Dis. 2021, 39, 119–139. [Google Scholar] [CrossRef]
  13. Parasa, S.; Desai, M.; Chandrasekar, V.T.; Patel, H.K.; Kennedy, K.F.; Roesch, T.; Spadaccini, M.; Colombo, M.; Gabbiadini, R.; Artifon, E.L.A.; et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis. JAMA Netw. Open 2020, 3, e2011335. [Google Scholar] [CrossRef]
  14. Kaafarani, H.M.A.M.; El Moheb, M.; Hwabejire, J.O.; Naar, L.; Christensen, M.A.B.; Breen, K.B.; Gaitanidis, A.; Alser, O.M.; Mashbari, H.; Bankhead-Kendall, B.; et al. Gastrointestinal complications in critically ill patients with COVID-19. Ann. Surg. 2020, 272, e61–e62. [Google Scholar] [CrossRef]
  15. Soheilipour, M.; Tabesh, E.; Sami, R.; Mansourian, M.; Tabesh, F.; Soltaninejad, F.; Dehghan, M.; Nikgoftar, N.; Gharavinia, A.; Ghasemi, K.; et al. Gastrointestinal manifestations in patients with coronavirus disease-2019 (COVID-19): Impact on clinical outcomes. J. Res. Med. Sci. 2022, 27, 32. [Google Scholar] [CrossRef]
  16. Sun, J.-K.; Liu, Y.; Zou, L.; Zhang, W.-H.; Li, J.-J.; Wang, Y.; Kan, X.-H.; Chen, J.-D.; Shi, Q.-K.; Yuan, S.-T. Acute gastrointestinal injury in critically ill patients with COVID-19 in Wuhan, China. World J. Gastroenterol. 2020, 26, 6087–6097. [Google Scholar] [CrossRef]
  17. Brenner, E.J.; Ungaro, R.C.; Gearry, R.B.; Kaplan, G.G.; Kissous-Hunt, M.; Lewis, J.D.; Ng, S.C.; Rahier, J.-F.; Reinisch, W.; Ruemmele, F.M.; et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry. Gastroenterology 2020, 159, 481–491.e3. [Google Scholar] [CrossRef]
  18. Lee, S.W.; Ha, E.K.; Yeniova, A.Ö.; Moon, S.Y.; Kim, S.Y.; Koh, H.Y.; Yang, J.M.; Jeong, S.J.; Moon, S.J.; Cho, J.Y.; et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: A nationwide cohort study with propensity score matching. Gut 2021, 70, 76–84. [Google Scholar] [CrossRef]
  19. Balaphas, A.; Gkoufa, K.; Meyer, J.; Peloso, A.; Bornand, A.; McKee, T.A.; Toso, C.; Popeskou, S.-G. COVID-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall. J. Hepatol. 2020, 73, 1566–1568. [Google Scholar] [CrossRef]
  20. Puig, G.; Giménez-Milà, M.; Campistol, E.; Caño, V.; Valcarcel, J.; Colomina, M.J. Development of concomitant diseases in COVID-19 critically ill patients. Rev. Esp. Anestesiol. Reanim. (Engl. Ed.) 2021, 68, 37–40. [Google Scholar] [CrossRef]
  21. Mattone, E.; Sofia, M.; Schembari, E.; Palumbo, V.; Bonaccorso, R.; Randazzo, V.; La Greca, G.; Iacobello, C.; Russello, D.; Latteri, S. Acute acalculous cholecystitis on a COVID-19 patient: A case report. Ann. Med. Surg. 2020, 58, 73–75. [Google Scholar] [CrossRef]
  22. Ying, M.; Lu, B.; Pan, J.; Lu, G.; Zhou, S.; Wang, D.; Li, L.; Shen, J.; Shu, J. COVID-19 with acute cholecystitis: A case report. BMC Infect. Dis. 2020, 20, 437. [Google Scholar] [CrossRef]
  23. Famularo, G.; Spada, P.L. COVID-19-related cholecystitis. Clin. Res. Hepatol. Gastroenterol. 2021, 45, 101635. [Google Scholar] [CrossRef]
  24. Barie, P.S.; Eachempati, S.R. Acute acalculous cholecystitis. Gastroenterol. Clin. N. Am. 2010, 39, 343–357. [Google Scholar] [CrossRef]
  25. McChesney, J.A.; Northup, P.G.; Bickston, S.J. Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: A case series and review of pathophysiology. Dig. Dis. Sci. 2003, 48, 1960–1967. [Google Scholar] [CrossRef] [PubMed]
  26. Treinen, C.; Lomelin, D.; Krause, C.; Goede, M.; Oleynikov, D. Acute acalculous cholecystitis in the critically ill: Risk factors and surgical strategies. Langenbecks Arch. Surg. 2015, 400, 421–427. [Google Scholar] [CrossRef] [PubMed]
  27. Walsh, K.; Goutos, I.; Dheansa, B. Acute acalculous cholecystitis in burns: A review. J. Burn. Care Res. 2018, 39, 724–728. [Google Scholar] [CrossRef] [PubMed]
  28. Croteau, D.; Flowers, C.; Kulick, C.G.; Brinker, A.; Kortepeter, C.M. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab. Neurology 2018, 90, e1548–52. [Google Scholar] [CrossRef] [PubMed]
  29. da Fonseca, L.G.; Barroso-Sousa, R.; Sabbaga, J.; Hoff, P.M. Acute acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin. Pract. 2014, 4, 635. [Google Scholar] [CrossRef]
  30. Porter, J.B.; Jick, H.; Dinan, B.J. Acute cholecystitis and thiazides. N. Engl. J. Med. 1981, 304, 954–955. [Google Scholar] [CrossRef] [PubMed]
  31. Tana, M.; Tana, C.; Cocco, G.; Iannetti, G.; Romano, M.; Schiavone, C. Acute acalculous cholecystitis and cardiovascular disease: A land of confusion. J. Ultrasound. 2015, 18, 317–320. [Google Scholar] [CrossRef] [PubMed]
  32. Barie, P.S.; Eachempati, S.R. Acute acalculous cholecystitis. Curr. Gastroenterol. Rep. 2003, 5, 302–309. [Google Scholar] [CrossRef]
  33. Neiderhiser, D.H. Acute acalculous cholecystitis induced by lysophosphatidylcholine. Am. J. Pathol. 1986, 124, 559–563. [Google Scholar] [PubMed]
  34. Hakala, T.; Nuutinen, P.J.; Ruokonen, E.T.; Alhava, E. Microangiopathy in acute acalculous cholecystitis. Br. J. Surg. 1997, 84, 1249–1252. [Google Scholar] [CrossRef] [PubMed]
  35. Kullmann, T.; Issekutz, Á.; Oláh, A.; Rácz, I. Acute acalculous cholecystitis: From common to rare causes. Orv. Hetil. 2014, 155, 89–91. [Google Scholar] [CrossRef] [PubMed]
  36. Orlando, R.; Gleason, E.; Drezner, A.D. Acute acalculous cholecystitis in the critically ill patient. Am. J. Surg. 1983, 145, 472–476. [Google Scholar] [CrossRef] [PubMed]
  37. Taoka, H. Experimental study on the pathogenesis of acute acalculous cholecystitis, with special reference to the roles of microcirculatory disturbances, free radicals and membrane-bound phospholipase A2. Gastroenterol. Jpn. 1991, 26, 633–644. [Google Scholar] [CrossRef] [PubMed]
  38. Vakkala, M.; Laurila, J.J.; Saarnio, J.; Koivukangas, V.; Syrjälä, H.; Karttunen, T.; Soini, Y.; Ala-Kokko, T.I. Cellular turnover and expression of hypoxic-inducible factor in acute acalculous and calculous cholecystitis. Crit. Care 2007, 11, R116. [Google Scholar] [CrossRef] [PubMed]
  39. Menendez, A.; Arena, E.T.; Guttman, J.A.; Thorson, L.; Vallance, B.A.; Vogl, W.; Finlay, B.B. Salmonella infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute typhoid fever. J. Infect. Dis. 2009, 200, 1703–1713. [Google Scholar] [CrossRef]
  40. Mourani, S.; Dobbs, S.M.; Genta, R.M.; Tandon, A.K.; Yoffe, B. Hepatitis A virus-associated cholecystitis. Ann. Intern. Med. 1994, 120, 398–400. [Google Scholar] [CrossRef]
  41. Hinnant, K.; Schwartz, A.; Rotterdam, H.; Rudski, C. Cytomegaloviral and cryptosporidial cholecystitis in two patients with AIDS. Am. J. Surg. Pathol. 1989, 13, 57–60. [Google Scholar] [CrossRef]
  42. Riediger, C.; Beimler, J.; Weitz, J.; Zeier, M.; Sauer, P. Cytomegalovirus infection of the major duodenal papilla in a renal allograft recipient with severe biliary obstruction and acalculous cholecystitis. Transpl. Infect. Dis. 2013, 15, E129–E133. [Google Scholar] [CrossRef]
  43. Agholi, M.; Aliabadi, E.; Hatam, G.R. Cystoisosporiasis-related human acalculous cholecystitis: The need for increased awareness. Pol. J. Pathol. 2016, 67, 270–276. [Google Scholar] [CrossRef]
  44. Agholi, M.; Heidarian, H.R.; Moghadami, M.; Hatam, G.R. First detection of acalculous cholecystitis associated with Sarcocystis infection in a patient with AIDS. Acta Parasitol. 2014, 59, 310–315. [Google Scholar] [CrossRef] [PubMed]
  45. Zar, F.A.; El-Bayoumi, E.; Yungbluth, M.M. Histologic proof of acalculous cholecystitis due to Cyclospora cayetanensis. Clin. Infect. Dis. 2001, 33, E140–E141. [Google Scholar] [CrossRef]
  46. Benator, D.A.; French, A.L.; Beaudet, L.M.; Levy, C.S.; Orenstein, J.M. Isospora belli infection associated with acalculous cholecystitis in a patient with AIDS. Ann. Intern. Med. 1994, 121, 663–664. [Google Scholar] [CrossRef] [PubMed]
  47. Knapp, P.E.; Saltzman, J.R.; Fairchild, P. Acalculous cholecystitis associated with microsporidial infection in a patient with AIDS. Clin. Infect. Dis. 1996, 22, 195–196. [Google Scholar] [CrossRef] [PubMed]
  48. Shinha, T.; Zabarsky, G. Acalculous Cholecystitis Due to Histoplasma capsulatum in a Patient with HIV Infection. ACG Case Rep. J. 2015, 2, 245–246. [Google Scholar] [CrossRef] [PubMed]
  49. Chen, P.L.; Lee, H.C.; Shan, Y.S.; Ko, N.Y.; Lee, N.Y.; Chang, C.M.; Wu, C.J.; Lee, C.C.; Ko, W.C. Respiratory failure and acalculous cholecystitis in a patient with AIDS and disseminated tuberculosis: Masking effect of fluoroquinolone monotherapy and immune restoration syndrome. Int. J. Infect. Dis. 2009, 13, e165–e168. [Google Scholar] [CrossRef] [PubMed]
  50. French, A.L.; Beaudet, L.M.; Benator, D.A.; Levy, C.S.; Kass, M.; Orenstein, J.M. Cholecystectomy in patients with AIDS: Clinicopathologic correlations in 107 cases. Clin. Infect. Dis. 1995, 21, 852–858. [Google Scholar] [CrossRef]
  51. Fujioka, K.; Nishimura, T.; Seki, M.; Kinoshita, M.; Mishima, N.; Irimajiri, S.; Yamato, M. Genotype 1 hepatitis E virus infection with acute acalculous cholecystitis as an extrahepatic symptom: A case report. Trop. Med. Health 2016, 44, 18. [Google Scholar] [CrossRef]
  52. Teshale, E.H.; Hu, D.J.; Holmberg, S.D. The two faces of hepatitis E virus. Clin. Infect. Dis. 2010, 51, 328–334. [Google Scholar] [CrossRef]
  53. Lee, G.Y.; Poovorawan, K.; Intharasongkroh, D.; Sa-Nguanmoo, P.; Vongpunsawad, S.; Chirathaworn, C.; Poovorawan, Y. Hepatitis E virus infection: Epidemiology and treatment implications. World J. Virol. 2015, 4, 343–355. [Google Scholar] [CrossRef] [PubMed]
  54. Young, C.; Lampe, R. Primary Epstein-Barr virus infection in an adolescent female complicated by acute acalculous cholecystitis. Cureus 2019, 11, e5044. [Google Scholar] [CrossRef] [PubMed]
  55. Simões, A.S.; Marinhas, A.; Coelho, P.; Ferreira, S. Acalculous acute cholecystitis during the course of an enteroviral infection. BMJ Case Rep. 2019, 12, e228306. [Google Scholar] [CrossRef] [PubMed]
  56. Iqbal, S.; Khajinoori, M.; Mooney, B. A case report of acalculous cholecystitis due to Salmonella paratyphi B. Radiol. Case Rep. 2018, 13, 1116–1118. [Google Scholar] [CrossRef] [PubMed]
  57. Poddighe, D.; Tresoldi, M.; Licari, A.; Marseglia, G.L. Acalculous acute cholecystitis in previously healthy children: General overview and analysis of pediatric infectious cases. Int. J. Hepatol. 2015, 2015, 459608. [Google Scholar] [CrossRef] [PubMed]
  58. Hariz, A.; Beji, I.; Hamdi, M.S.; Cherif, E. Brucellosis, an uncommon cause of acute acalculous cholecystitis: Two new cases and concise review. BMJ Case Rep. 2019, 12, e229616. [Google Scholar] [CrossRef] [PubMed]
  59. Szvalb, A.D.; Kontoyiannis, D.P. Acute acalculous cholecystitis due to Fusarium species and review of the literature on fungal cholecystitis. Mycoses 2019, 62, 847–853. [Google Scholar] [CrossRef]
  60. Castelijn, D.A.R.; Wattel-Louis, G.H. An acute acalculous cholecystitis in a returned travel couple. PLoS Negl. Trop. Dis. 2018, 12, e0006177. [Google Scholar] [CrossRef]
  61. Mahapatra, R.; Cohen, D.; Viccellio, A.W.; Sasson, A.; Bandovic, J.; Spitzer, E.D.; Lier, A.; Marcos, L.A. Acute acalculous cholecystitis as a manifestation of ehrlichiosis. Ticks Tick. Borne Dis. 2019, 10, 1033–1034. [Google Scholar] [CrossRef]
  62. Du, M.; Suo, J.; Liu, B.; Xing, Y.; Chen, L.; Liu, Y. Post-ERCP infection and its epidemiological and clinical characteristics in a large Chinese tertiary hospital: A 4-year surveillance study. Antimicrob. Resist. Infect. Control. 2017, 6, 131. [Google Scholar] [CrossRef] [PubMed]
  63. Takeshita, S.; Nakamura, H.; Kawakami, A.; Fukushima, T.; Gotoh, T.; Ichikawa, T.; Tsujino, A.; Ida, H.; Toriyama, K.; Hayashi, T.; et al. Hepatitis B-related polyarteritis nodosa presenting necrotizing vasculitis in the hepatobiliary system successfully treated with lamivudine, plasmapheresis and glucocorticoid. Intern. Med. 2006, 45, 145–149. [Google Scholar] [CrossRef] [PubMed]
  64. Janssen, H.L.; van Zonneveld, M.; van Nunen, A.B.; Niesters, H.G.; Schalm, S.W.; de Man, R.A. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur. J. Gastroenterol. Hepatol. 2004, 16, 801–807. [Google Scholar] [CrossRef]
  65. Meier, M.; Holl-Ulrich, K.; Perras, B. A rare manifestation of cryoglobulinemic vasculitis: Acalculous cholecystitis. Clin. Gastroenterol. Hepatol. 2005, 3, A26. [Google Scholar] [CrossRef]
  66. Ono, S.K.; Bassit, L.; Van Vaisberg, V.; Avancini Ferreira Alves, V.; Caldini, E.G.; Herman, B.D.; Shabman, R.; Fedorova, N.B.; Paranaguá-Vezozzo, D.; Sampaio, C.T.; et al. Acute acalculous cholecystitis during zika virus infection in an immunocompromised patient. Hepatology 2018, 67, 2051–2054. [Google Scholar] [CrossRef] [PubMed]
  67. Guarner, J.; Shieh, W.J.; Morgan, J.; Bragg, S.L.; Bajani, M.D.; Tappero, J.W.; Zaki, S.R. Leptospirosis mimicking acute cholecystitis among athletes participating in a triathlon. Hum. Pathol. 2001, 32, 750–752. [Google Scholar] [CrossRef] [PubMed]
  68. Walker, D.H.; Lesesne, H.R.; Varma, V.A.; Thacker, W.C. Rocky Mountain spotted fever mimicking acute cholecystitis. Arch. Intern. Med. 1985, 145, 2194–2196. [Google Scholar] [CrossRef] [PubMed]
  69. Wani, I. Gallbladder ascariasis. Turk. J. Gastroenterol. 2011, 22, 178–182. [Google Scholar] [CrossRef] [PubMed]
  70. Khuroo, M.S.; Rather, A.A.; Khuroo, N.S.; Khuroo, M.S. Hepatobiliary and pancreatic ascariasis. World J. Gastroenterol. 2016, 22, 7507–7517. [Google Scholar] [CrossRef]
  71. Araki, H.; Shimizu, S.; Hayashi, K.; Yamada, T.; Kusakabe, A.; Kanie, H.; Mizuno, Y.; Kojima, I.; Saitou, A.; Nagao, K.; et al. Acute Acalculous Cholecystitis Caused by Giardia lamblia. Intern. Med. 2017, 56, 1657–1662. [Google Scholar] [CrossRef]
  72. Colle, I.; Van Vlierberghe, H.; Brenard, R.; Troisi, R.; de Hemptinne, B.; Navez, B.; De Coninck, S.; De Vos, M. Biliary complications of large Echinococcus granulosus cysts: Report of 2 cases and review of the literature. Acta Clin. Belg. 2002, 57, 349–354. [Google Scholar] [CrossRef]
  73. Iaria, C.; Arena, L.; Di Maio, G.; Fracassi, M.G.; Leonardi, M.S.; Famulari, C.; Cascio, A. Acute acalculous cholecystitis during the course of primary Epstein-Barr virus infection: A new case and a review of the literature. Int. J. Infect. Dis. 2008, 12, 391–395. [Google Scholar] [CrossRef] [PubMed]
  74. Chen, Y.; Kong, J.; Wu, S. Cholesterol gallstone disease: Focusing on the role of gallbladder. Lab. Investig. 2015, 95, 124–131. [Google Scholar] [CrossRef]
  75. Xiao, Z.L.; Rho, A.K.; Biancani, P.; Behar, J. Effects of bile acids on the muscle functions of guinea pig gallbladder. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 283, G87–G94. [Google Scholar] [CrossRef]
  76. Huang, Y.; Mei, F.; Yu, B.; Zhang, H.-J.; Han, J.; Jiang, Z.-Y.; Zhou, D.-S. Distribution of the interstitial Cajal-like cells in the gallbladder and extrahepatic biliary duct of the guinea-pig. Acta Histochem. 2009, 111, 157–165. [Google Scholar] [CrossRef]
  77. Falk, V.; Low, G.; Bigam, D.; Sandha, G. Acute acalculous cholecystitis of an intrahepatic gallbladder causing Mirizzi’s syndrome. BMJ Case Rep. 2018, 2018, bcr2018224365. [Google Scholar] [CrossRef] [PubMed]
  78. Owen, C.C.; Jain, R. Acute acalculous cholecystitis. Curr. Treat. Options Gastro. 2005, 8, 99–104. [Google Scholar] [CrossRef] [PubMed]
  79. Shin, S.J.; Na, K.S.; Jung, S.S.; Bae, S.C.; Yoo, D.H.; Kim, S.Y.; Kim, T.H. Acute acalculous cholecystitis associated with systemic lupus erythematosus with Sjogren’s syndrome. Korean J. Intern. Med. 2002, 17, 61–64. [Google Scholar] [CrossRef]
  80. Otsuka, Y.; Inoue, Y. So-called acute acalculous cholecystitis in macrophage activation syndrome. Intern. Med. 2016, 55, 3043–3046. [Google Scholar] [CrossRef]
  81. Thampy, R.; Khan, A.; Zaki, I.H.; Wei, W.; Korivi, B.R.; Staerkel, G.; Bathala, T.K. Acute acalculous cholecystitis in hospitalized patients with hematologic malignancies and prognostic importance of gallbladder ultrasound findings. J. Ultrasound Med. 2019, 38, 51–61. [Google Scholar] [CrossRef]
  82. Kuroi, Y.; Imazato, D.; Yamazaki, K.; Kasuya, H. Acute cholecystitis in patients with stroke. Neurol. India 2019, 67, 439–441. [Google Scholar] [CrossRef]
  83. Yasuda, H.; Takada, T.; Kawarada, Y.; Nimura, Y.; Hirata, K.; Kimura, Y.; Wada, K.; Miura, F.; Hirota, M.; Mayumi, T.; et al. Unusual cases of acute cholecystitis and cholangitis: Tokyo guidelines. J. Hepatobiliary Pancreat. Surg. 2007, 14, 98–113. [Google Scholar] [CrossRef] [PubMed]
  84. Yombi, J.C.; Meuris, C.M.; Van Gompel, A.M.; Ben Younes, M.; Vandercam, B.C. Acalculous cholecystitis in a patient with Plasmodium falciparum infection: A case report and literature review. J. Travel. Med. 2006, 13, 178–180. [Google Scholar] [CrossRef] [PubMed]
  85. Harris, E.F.; Younger, E.; Llewelyn, M.B. Acalculous cholecystitis occurring in the context of Plasmodium malariae infection: A case report. J. Med. Case Rep. 2013, 7, 197. [Google Scholar] [CrossRef]
  86. Curley, J.M.; Mody, R.M.; Gasser, R.A., Jr. Malaria caused by Plasmodium vivax complicated by acalculous cholecystitis. Am. J. Trop. Med. Hyg. 2011, 85, 42–49. [Google Scholar] [CrossRef] [PubMed]
  87. Agergaard, J.; Larsen, C.S. Acute acalculous cholecystitis in a patient with primary Epstein-Barr virus infection: A case report and literature review. Int. J. Infect. Dis. 2015, 35, 67–72. [Google Scholar] [CrossRef] [PubMed]
  88. Dinulos, J.; Mitchell, D.K.; Egerton, J.; Pickering, L.K. Hydrops of the gallbladder associated with Epstein-Barr virus infection: A report of two cases and review of the literature. Pediatr. Infect. Dis. J. 1994, 13, 924–929. [Google Scholar] [CrossRef]
  89. Ntelis, K.; Mazarakis, D.; Sapountzis, A.; Zissi, D.; Sparangi, S.; Xidia, N.; Velissaris, D. Acute Acalculous Cholecystitis Associated with Epstein-Barr Infection: A Case Report and Review of the Literature. Case Rep. Med. 2020, 2020, 9029601. [Google Scholar] [CrossRef]
  90. Roy, J.; Sahu, N.; Golamari, R.; Vunnam, R. Acute Acalculous Cholecystitis in a Patient with COVID-19 and a LVAD. J. Card. Fail. 2020, 26, 639. [Google Scholar] [CrossRef]
  91. Alhassan, S.M.; Iqbal, P.; Fikrey, L.; Mohamed Ibrahim, M.I.; Qamar, M.S.; Chaponda, M.; Munir, W. Post COVID 19 acute acalculous cholecystitis raising the possibility of underlying dysregulated immune response, a case report. Ann. Med. Surg. 2020, 60, 434–437. [Google Scholar] [CrossRef]
  92. D’Introno, A.; Gatti, P.; Manca, G.; D’Amuri, A.; Minniti, S.; Ciracì, E. Acute acalculous cholecystitis as an early manifestation of COVID-19: Case report and literature review. Acta Biomed. 2022, 93 (Suppl. S1), e2022207. [Google Scholar] [CrossRef]
  93. Scutari, R.; Piermatteo, L.; Ciancio Manuelli, M.; Ceccherini-Silberstein, F. Long-Term SARS-CoV-2 Infection Associated with Viral Disseminationin Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis. Life 2020, 10, 302. [Google Scholar] [CrossRef]
  94. Lovece, A.; Asti, E.; Bruni, B.; Bonavina, L. Subtotal laparoscopic cholecystectomy for gangrenous gallbladder during recovery from COVID-19 pneumonia. Int. J. Surg. Case Rep. 2020, 72, 335–338. [Google Scholar] [CrossRef]
  95. Bruni, A.; Garofalo, E.; Zuccalà, V.; Currò, G.; Torti, C.; Navarra, G.; De Sarro, G.; Navalesi, P.; Longhini, F.; Ammendola, M. Histopathological findings in a COVID-19 patient affected by ischemic gangrenous cholecystitis. World J. Emerg. Surg. 2020, 15, 43. [Google Scholar] [CrossRef]
  96. Zhang, Y.; Xiao, M.; Zhang, S.; Xia, P.; Cao, W.; Jiang, W.; Chen, H.; Ding, X.; Zhao, H.; Zhang, H.; et al. Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19. N. Engl. J. Med. 2020, 382, e38. [Google Scholar] [CrossRef]
  97. Karamyan, V.T. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? Physiol. Rep. 2021, 9, e14796. [Google Scholar] [CrossRef]
  98. Gupta, A.; Madhavan, M.V.; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T.S.; Bikdeli, B.; Ahluwalia, N.; Ausiello, J.C.; Wan, E.Y.; et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020, 26, 1017–1032. [Google Scholar] [CrossRef]
  99. Zong, H.; Yin, B.; Zhou, H.; Cai, D.; Ma, B.; Xiang, Y. Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. Tumour Biol. 2015, 36, 5171–5177. [Google Scholar] [CrossRef]
  100. Bozada-Gutiérrez, K.; Trejo-Avila, M.; Chávez-Hernández, F.; Parraguirre-Martínez, S.; Valenzuela-Salazar, C.; Herrera-Esquivel, J.; Moreno-Portillo, M. Surgical treatment of acute cholecystitis in patients with confirmed COVID-19: Ten case reports and review of literature. World J. Clin. Cases 2022, 10, 1296–1310. [Google Scholar] [CrossRef]
  101. Asti, E.; Lovece, A.; Bonavina, L. Gangrenous cholecystitis during hospitalization for SARS-CoV2 infection. Updates Surg. 2020, 72, 917–919. [Google Scholar] [CrossRef]
  102. Cirillo, B.; Brachini, G.; Crocetti, D.; Sapienza, P.; Mingoli, A. Acalcolous Hemorrhagic Cholecystitis and SARS-CoV-2 Infection. Br. J. Surg. 2020, 107, e524. [Google Scholar] [CrossRef]
  103. Franch-Llasat, D.; Sabaté-Ortigues, R.; Bellaubí-Pallarés, N.; Andrés-Castrillo, F.; Comí-Codina, S.; Roche-Campo, F. The incidence of acute acalculous cholecystitis in critically ill COVID-19 patients. Acute Crit. Care 2022, 37, 678–680. [Google Scholar] [CrossRef] [PubMed]
  104. Barbachowska, A.; Gozdowska, J.; Piotrowska-Kownacka, D.; Sawicka, M.; Dęborska-Materkowska, D.; Skolimowska, E.; Durlik, M. Extrapulmonary Manifestations of SARS-CoV-2: A Report of 3 Cases and a Literature Review. Ann. Transplant. 2022, 27, e935874. [Google Scholar] [CrossRef]
  105. Deif, M.A.; Mounir, A.M.; Abo-Hedibah, S.A.; Abdel Khalek, A.M.; Elmokadem, A.H. Outcome of percutaneous drainage for septic complications coexisted with COVID-19. World J. Radiol. 2022, 14, 91–103. [Google Scholar] [CrossRef]
  106. Wahid, N.; Bhardwaj, T.; Borinsky, C.; Tavakkoli, M. Acute Acalculous Cholecystitis During Severe COVID-19 Hospitalizations. Am. J. Gastroenterol. 2020, 115, S794. [Google Scholar] [CrossRef]
  107. Liapis, S.C.; Stavrou, A.; Perivoliotis, K.; Christodoulou, P.; Kalodimos, G.; Kitsakis, G.; Kapatou, K.; Ziamas, D.; Lytras, D. Laparoscopic cholecystectomy for acalculous, gangrenous cholecystitis on an outpatient COVID-19 adult: A case report. J. Surg. Case Rep. 2022, 2022, rjac205. [Google Scholar] [CrossRef]
  108. Hajebi, R.; Habibi, P.; Maroufi, S.F.; Bahreini, M.; Miratashi Yazdi, S.A. COVID-19 patients presenting with gangrenous acalculous cholecystitis: Report of two cases. Ann. Med. Surg. 2022, 76, 103534. [Google Scholar] [CrossRef] [PubMed]
  109. Alam, W.; Karam, K. Gangrenous Cholecystitis as a Potential Complication of COVID-19: A Case Report. Clin. Med. Insights Case Rep. 2021, 14, 11795476211042459. [Google Scholar] [CrossRef]
  110. De Simone, B.; Abu-Zidan, F.M.; Chouillard, E.; Di Saverio, S.; Sartelli, M.; Podda, M.; Gomes, C.A.; Moore, E.E.; Moug, S.J.; Ansaloni, L.; et al. The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis? World J. Emerg. Surg. 2022, 17, 61. [Google Scholar] [CrossRef]
  111. Abaleka, F.I.; Nigussie, B.; Bedanie, G.; Mohammed, A.; Galiboglu, S. Acute Acalculous Cholecystitis Due to COVID-19, an Unusual Presentation. Cureus 2021, 13, e15431. [Google Scholar] [CrossRef]
  112. Hassani, A.H.; Beheshti, A.; Almasi, F.; Ketabi Moghaddam, P.; Azizi, M.; Shahrokh, S. Unusual gastrointestinal manifestations of COVID-19: Two case reports. Gastroenterol. Hepatol. Bed Bench. 2020, 13, 410–414. [Google Scholar] [PubMed]
  113. Safari, S.; Keyvani, H.; Malekpour Alamdari, N.; Dehghanian, A.; Razavi Hashemi, M.; Nemati Honar, B.; Aminian, A. Abdominal Surgery in Patients with COVID-19: Detection of SARS-CoV-2 in Abdominal and Adipose Tissues. Ann. Surg. 2020, 272, e253–e256. [Google Scholar] [CrossRef]
  114. Basukala, S.; Rijal, S.; Karki, S.; Basukala, B.; Gautam, A.R. Spontaneous gallbladder perforation in patient with COVID-19—A case report and review of literature. J. Surg. Case Rep. 2021, 2021, rjab496. [Google Scholar] [CrossRef]
  115. Futagami, H.; Sato, H.; Yoshida, R.; Yasui, K.; Yagi, T.; Fujiwara, T. Acute acalculous cholecystitis caused by SARS-CoV-2 infection: A case report and literature review. Int. J. Surg. Case Rep. 2022, 90, 106731. [Google Scholar] [CrossRef]
  116. Chen, C.; Riyahi, S.; Prince, M.; Thomas, C.; RoyChoudury, A.; Browne, W.F.; Sweeney, E.; Margolis, D.J. Predictors of biliary intervention in patients hospitalized for COVID-19. Abdom. Radiol. 2022, 47, 1891–1898. [Google Scholar] [CrossRef]
  117. Ielpo, B.; Prieto, M.; Ortega, I.; Balibrea, J.M.; Rubio-Pérez, I.; Juvany, M.; Gómez-Bravo, M.; Ramia, J.M. National survey on the treatment of cholelitiasis in Spain during the initial period of the COVID-19 pandemic. Cir. Esp. (Engl. Ed.) 2021, 99, 346–353. [Google Scholar] [CrossRef]
  118. Narvaez, F.J.R.; Cooper, C.; Brewer, J.J.; Schwaitzberg, S.D.; Guo, W.A. Do We "Do No Harm" in the Management of Acute Chole-cystitis in COVID-19 Patients? Am. Surg. 2020, 86, 748–750. [Google Scholar] [CrossRef]
  119. Lisotti, A.; Bacchilega, I.; Linguerri, R.; Fusaroli, P. Endoscopic ultrasound-guided gallbladder drainage as a strategy to overcome shortage of operating rooms and intensive care unit beds during COVID-19 crisis. Endoscopy 2020, 52, E263–E264. [Google Scholar] [CrossRef]
  120. Munavalli, G.G.; Guthridge, R.; Knutsen-Larson, S.; Brodsky, A.; Matthew, E.; Landau, M. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermalfillers: A challenging clinical conundrum in diagnosis and treatment. Arch. Dermatol. Res. 2021, 314, 1–15. [Google Scholar] [CrossRef]
  121. Yokoe, M.; Hata, J.; Takada, T.; Strasberg, S.M.; Asbun, H.J.; Wakabayashi, G.; Kozaka, K.; Endo, I.; Deziel, D.J.; Miura, F.; et al. Tokyo Guidelines 2018: Diagnostic criteria and severity grading of acute cholecystitis (with videos). J. Hepatobiliary Pancreat. Sci. 2018, 25, 41–54. [Google Scholar] [CrossRef]
  122. Wakabayashi, G.; Iwashita, Y.; Hibi, T.; Takada, T.; Strasberg, S.M.; Asbun, H.J.; Endo, I.; Umezawa, A.; Asai, K.; Suzuki, K.; et al. Tokyo Guidelines 2018: Surgical management of acute cholecystitis: Safe steps in laparoscopic cholecystectomy for acute cholecystitis (with videos). J. Hepatobiliary Pancreat. Sci. 2018, 25, 73–86. [Google Scholar] [CrossRef]
  123. Gouma, D.J.; Oberto, H. Acute calculous cholecystitis. What is new in diagnosis and therapy? HPB Surg. 1992, 6, 69–78. [Google Scholar] [CrossRef]
  124. Chen, X.; Tang, S.; Yu, D.; Liu, Z. Logistic regression analysis of gallbladder lesions of ≥1 cm in diameter diagnosed by ultrasound. Chin. J. Med. Imaging 2013, 12, 447–450. [Google Scholar]
  125. Chawla, A.; Bosco, J.I.; Lim, T.C.; Srinivasan, S.; The, H.S.; Shenoy, J.N. Imaging of acute cholecystitis and cholecystitis-associated complications in the emergency setting. Singap. Med. J. 2015, 56, 438–444, quiz 444. [Google Scholar] [CrossRef]
  126. Yeo, D.M.; Jung, S.E. Differentiation of acute cholecystitis from chronic cholecystitis: Determination of useful multidetector computed tomography findings. Medicine 2018, 97, e11851. [Google Scholar] [CrossRef]
  127. Shafiq, M.; Zafar, Y. Acute acalculous cholecystitis in the setting of negative ultrasound and computed tomography scan of the abdomen. Cureus 2018, 10, e2243. [Google Scholar] [CrossRef]
  128. Shiryajev, Y.N.; Glebova, A.V.; Koryakina, T.V.; Kokhanenko, N.Y. Acute acalculous cholecystitis complicated by MRCP-confirmed Mirizzi syndrome: A case report. Int. J. Surg. Case Rep. 2012, 3, 193–195. [Google Scholar] [CrossRef]
  129. Hassan, I.M.; Que, L.; Rutland, M. The role of glyceryl trinitrate (GTN) in 99m Tc-HIDA with morphine provocation scan for the investigation of type III sphincter of oddi dysfunction (SOD). J. Nucl. Med. 2016, 57 (Suppl. S2), 646. [Google Scholar]
  130. Adachi, T.; Eguchi, S.; Muto, Y. Pathophysiology and pathology of acute cholecystitis: A secondary publication of the Japanese version from 1992. J. Hepatobiliary Pancreat. Sci. 2022, 29, 212–216. [Google Scholar] [CrossRef] [PubMed]
  131. Jones, M.W.; Ferguson, T. Acalculous Cholecystitis. Updated 24 April 2023. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK459182/ (accessed on 11 February 2024).
  132. Fiore, D.; Saragò, M.; Rizzuto, A.; Indolfi, C.; Pulitanò, L.; De Rosa, S.; Amaddeo, A.; Bozzarello, C.; Iannello, A.M.; Sammarco, G. 301 Acute acalculous cholecystitis and cardiovascular disease, which came first? Eur. Heart J. Suppl. 2022, 24 (Suppl. SK), K184. [Google Scholar] [CrossRef]
  133. Saragò, M.; Fiore, D.; De Rosa, S.; Amaddeo, A.; Pulitanò, L.; Bozzarello, C.; Iannello, A.M.; Sammarco, G.; Indolfi, C.; Rizzuto, A. Acute acalculous cholecystitis and cardiovascular disease, which came first? After two hundred years still the classic chicken and eggs debate: A review of literature. Ann. Med. Surg. 2022, 78, 103668. [Google Scholar] [CrossRef]
  134. Okamoto, K.; Suzuki, K.; Takada, T.; Strasberg, S.M.; Asbun, H.J.; Endo, I.; Iwashita, Y.; Hibi, T.; Pitt, H.A.; Umezawa, A.; et al. Tokyo guidelines 2018: Flowchart for the management of acute cholecystitis. J. Hepatobiliary Pancreat. Sci. 2018, 25, 55–72. [Google Scholar] [CrossRef]
  135. Noh, S.Y.; Gwon, D.I.; Ko, G.Y.; Yoon, H.K.; Sung, K.B. Role of percutaneous cholecystostomy for acute acalculous cholecystitis: Clinical outcomes of 271 patients. Eur. Radiol. 2018, 28, 1449–1455. [Google Scholar] [CrossRef]
  136. Gu, M.G.; Kim, T.N.; Song, J.; Nam, Y.J.; Lee, J.Y.; Park, J.S. Risk factors and therapeutic outcomes of acute acalculous cholecystitis. Digestion 2014, 90, 75–80. [Google Scholar] [CrossRef]
  137. Real-Noval, H.; Fernández-Fernández, J.; Soler-Dorda, G. Predicting factors for the diagnosis of gangrene acute cholecystitis. Cir. Cir. 2019, 87, 443–449. [Google Scholar]
  138. Shapiro, M.J.; Luchtefeld, W.B.; Kurzweil, S.; Kaminski, D.L.; Durham, R.M.; Mazuski, J.E. Acute acalculous cholecystitis in the critically ill. Am. Surg. 1994, 60, 335–339. [Google Scholar]
  139. Chung, Y.H.; Ryoung Choi, E.; Kim, K.M.; Kim, M.J.; Lee, J.K.; Lee, K.T.; Choo, I.W. Can percutaneous cholecystostomy be a definitive management for acute acalculous cholecystitis? J. Clin. Gastroenterol. 2012, 46, 216–219. [Google Scholar] [CrossRef]
  140. Li, Y.; Liu, H.; Li, W. Feasibility and efficacy of ultrasound-guided percutaneous transhepatic cholecystectomy and drainage in the treatment of acute noncalculous cholecystitis in the elderly. J. Clin. Gastroenterol. 2015, 27, 141–143. [Google Scholar]
  141. Morales-Maza, J.; Rodríguez-Quintero, J.; Santes, O.; Hernández-Villegas, A.; Clemente-Gutiérrez, U.; Sánchez-Morales, G.; Terán-Ellis, S.M.Y.; Pantoja, J.; Mercado, M. Percutaneous cholecystostomy as treatment for acute cholecystitis: What has happened over the last five years? A literature review. Rev. Gastroenterol. Mex. 2019, 84, 482–491. [Google Scholar] [CrossRef]
  142. Dvorak, P.; Hoffmann, P.; Renc, O.; Dusek, T.; Rejchrt, S.; Slezak, O.; Vyroubal, P. Percutaneous cholecystostomy in the management of acute cholecystitis—10 years of experience. Wideochir Inne Tech. Maloinwazyjne 2019, 14, 516–525. [Google Scholar] [CrossRef] [PubMed]
  143. Balmadrid, B. Recent advances in management of acalculous cholecystitis. F1000Research 2018, 7, 1660. [Google Scholar] [CrossRef]
  144. Mori, Y.; Itoi, T.; Baron, T.H.; Takada, T.; Strasberg, S.M.; Pitt, H.A.; Ukai, T.; Shikata, S.; Noguchi, Y.; Teoh, A.Y.B.; et al. Tokyo guidelines 2018: Management strategies for gallbladder drainage in patients with acute cholecystitis (with videos). J. Hepatobiliary Pancreat. Sci. 2018, 25, 87–95. [Google Scholar] [CrossRef]
  145. Irani, S.; Ngamruengphong, S.; Teoh, A.; Will, U.; Nieto, J.; Abu Dayyeh, B.K.; Gan, S.I.; Larsen, M.; Yip, H.C.; Topazian, M.D.; et al. Similar efficacies of endoscopic ultrasound gallbladder drainage with a lumen-apposing metal stent versus percutaneous transhepatic gallbladder drainage for acute cholecystitis. Clin. Gastroenterol. Hepatol. 2017, 15, 738–745. [Google Scholar] [CrossRef]
  146. Jain, D.; Bhandari, B.S.; Agrawal, N.; Singhal, S. Endoscopic ultrasound-guided gallbladder drainage using a lumen-apposing metal stent for acute cholecystitis: A systematic review. Clin. Endosc. 2018, 51, 450–462. [Google Scholar] [CrossRef]
  147. Kawakami, H.; Maguchi, H.; Mukai, T.; Hayashi, T.; Sasaki, T.; Isayama, H.; Nakai, Y.; Yasuda, I.; Irisawa, A.; Niido, T.; et al. A multicenter, prospective, randomized study of selective bile duct cannulation performed by multiple endoscopists: The BIDMEN study. Gastrointest. Endosc. 2012, 75, 362–372.e1. [Google Scholar] [CrossRef]
Table 1. Acute (acalculous) cholecystitis in COVID-19 patients.
Table 1. Acute (acalculous) cholecystitis in COVID-19 patients.
AuthorPatient Gender—ComorbiditiesAgeTime of Onset—Clinical CharacteristicsSymptoms—Findings—Diagnosis—SeverityManagementOutcome
Non-ICU-associated COVID-19 AAC
Balaphas, 2020 [19]Female84AAC onset: 4 days after fever

Sepsis due to pyelonephritis—ARDS due to COVID-19—10 days from hospital admission to death		Right upper quadrant pain, positive Murphy, increased CRP, ARDS. Ultrasonography and CT scan: no gallbladder perforation. Histological
analysis of the gallbladder did not demonstrate any inflammation,
but quantitative reverse transcriptase PCR (qRT-PCR)
revealed the presence of SARS-CoV-2 in all 3 sampled regions of
the gallbladder wall.		Supportive care, ceftriaxone, metronidazole,
laparoscopic cholecystectomy		Death (multiorgan failure)
Balaphas, 2020 [19]Male
CKD-dialysis, DM2, ArtHTN, modAoS		83AAC onset: 5 days after fever

Respiratory symptoms due to COVID-19		Right upper quadrant pain, positive Murphy
sign, increased CRP, white blood cells, hepatic enzymes.
Ultrasonography: 4 mm thickening of the gallbladder
wall, presence of peri-vesicular liquid, absence of gallstones.		Conservative management with
ceftriaxone and metronidazole		Recovered
Ying, 2020 [22]Female68AAC onset: after 10 days of hospitalization for COVID-19 pneumonia

6 days of fever—COVID-19 pneumonia		Right upper
quadrant pain, diarrhea, Murphy’s sign after 10
days of hospitalization, fever, elevated CRP; bile was negative for SARS-CoV-2. CT scan: distended gallbladder, hyperplasia
of the gallbladder wall, and biliary sludge;
CT scan did not show gallstones in the gallbladder.		Ultrasound-guided percutaneous transhepatic gallbladder
drainage (PTGD), antibacterial
and anti-viral lopinavir/ritonavir combined with human
interferon alfa-1b inhalation		Recovered
Lovece, 2020 [94]Male42AAC onset: after 10 days of hospitalization for COVID-19 pneumonia

7 days of fever—hypoxemia—CPAP		Nausea and upper-quadrant abdominal pain, afebrile, diffuse abdominal tenderness, rebound pain.
Ultrasound and CT scan: absence of contrast enhancement of the gallbladder and microperforation of the fundus		Emergency laparoscopic cholecystectomyRecovered
Bozada-Gutiérrez, 2022 [100]Females: 4
Males: 6		Mean age: 47.1 (range 20–74)AAC onset: not defined

COVID-19 pneumonia (n = 6)
Asymptomatic (n = 4)
ICU admission after AAC (n = 5)
Parkland grading scale
3 (n = 2)
4 (n = 2)
5 (n = 6)		Right upper quadrant pain (n = 10), right upper
quadrant mass (n = 6), and positive Murphy’s sign (n = 10).
All patients underwent chest computed tomography (CT) scans prior to surgery. Also,
all patients underwent gallbladder ultrasound.
Only one acalculous.		Two patients required preoperative endoscopic retrograde cholangiopancreatography
(ERCP).
All patients were treated with urgent/early Lap-C. Eight surgeries were completed
via laparoscopy, and two patients required conversion to open cholecystectomy due to
operative difficulty.		Death: 1
Recovered: 9
Asti, 2020 [101]F: 86
M: 72
M: 40		NRAAC onset: not defined;
all recovering from COVID-19 pneumonia		Acute abdomen
CT: acute acalculous cholecystitis.		Emergency
laparoscopy confirmed gallbladder gangrene in all associated
with fundic microperforation in the youngest patient,
and cholecystectomy was completed without complications
and no conversion		Recovered
Cirillo, 2020 [102]Male79AAC onset: after 7 days of hospitalization for COVID-19 pneumonia

COVID-19 during hospitalization
in a rehabilitation clinic after
hip replacement for fracture		Anemia/bleeding, abdominal tenderness
on the right upper quadrant. CT scan: perforated acalculous gallbladder.		Emergency
cholecystectomy		Recovered
Barbachowska, 2022 [104]Male
living-donor
kidney transplantation (mother) in 2017 due to end-stage kidney
disease in course of IgA nephropathy		34AAC onset: recurrent fever up to 39.5 °C lasting for 3 weeks—COVID-19 pneumoniaChronic fatigue, back pain, bloating, nausea, pain in upper
quadrant of the abdomen, loss of appetite. CT scan, cholangio-MRI: acalculous cholecystitis with presence of pericholecystitis
and increased density and edema of surrounding tissues.		LMWH, antibioticsRecovered
D’ Introno, 2022 [92]Male
DM2, artHTN		50AAC onset: after 6 days of generalized abdominal pain, low fever,
nausea, and vomiting

Dehydration, COVID-19 positive with no respirator symptoms		Tenderness on the right upper quadrant and in the
epigastrium, positive Murphy’s sign. Ultrasonography and CT scan: gangrenous gallbladder with perihepatic
fluid.		Initial antibiotics (piperacillin/tazobactam)
failed, laparoscopic
cholecystectomy		Recovered
Deif, 2022 [105]Male
DM		55AAC onset: not defined

COVID-19 pneumonia—ambulatory		Abdominal pain. Ultrasound: acute
cholecystitis.		Percutaneous cholecystostomyRecovered
Liapis, 2022 [107]Male53AAC onset: after COVID-19 infection for 10 days

Fever spikes, mild dyspnea, non-productive cough		Epigastric pain and fever.
Right upper quadrant tenderness and a positive Murphy’s sign.
Ultrasound and CT scan: gangrenous gallbladder with no sign of perforation.		Laparoscopic cholecystectomy and antibioticsRecovered
Hajebi, 2022 [108]Female
artHTN, appendectomy		86AAC onset: 1 day after generalized abdominal pain

COVID-19 pneumonia—ambulatory		Generalized abdominal pain, vomiting, loss of appetite, weight loss, severe tenderness in right upper and lower
quadrants, epigastrium, and hypogastrium. Ultrasound and CT scan: gallbladder distension with surrounding fluid.		Open cholecystectomyRecovered
Hajebi, 2022 [108]Male82AAC onset: not defined

COVID-19 pneumonia—ambulatory		Abdominal pain and tenderness in right upper quadrant, vomiting. CT scan: emphysematous cholecystitis.Open cholecystectomyRecovered
Futagami, 2022 [115]Male
CKD on dialysis		42AAC onset: after 7 days in ward for fever and cough

COVID-19 pneumonia—hypoxia—increased oxygen administration by non-rebreather mask 		Abdominal pain. CT scan: moderate grade AAC.Percutaneous
transhepatic gallbladder drainage (PTGBD), antibitiotics and laparoscopic cholecystectomy when patient was COVID (−)		Recovered
Alam, 2021 [109]Female84AAC onset: after 2 days of generalized abdominal pain, vomiting, and diarrhea


COVID-19 pneumonia—intubation due to septic shock		Generalized abdominal pain, positive
Murphy’s sign, vomiting, diarrhea, altered
general status, respiratory distress,
desaturation, hypotensive.
CT scan: Acute ischemic gangrenous cholecystitis.		Conservative initially and scheduled for percutaneous drainage. Cardiac arrest.Death (septic shock)
De Simone, 2022 ChoCo-W study [110]The aim of the ChoCO-W
global prospective study was to compare the clinical course,
biological and radiological findings, and clinical outcomes
of AC in patients who have COVID-19 disease with those
who do not have it		COVID: 180.
Non-COVID: 2412.
Age: 63.93 (15.8)
vs.
96 (53.3%).		AAC onset: not defined

PCR-positive COVID-19 patients with acute cholecystitis irrespective of clinical status		Acalculous cholecystitis: COVID 8 (4.6%) vs. non-COVID 93 (3.9%) p = 0.18.All interventionsMortality rate was 13.4% (24/180) in the COVID group
and 1.7% (40/2412) in the non-COVID group (p < 0.0001).
Abaleka, 2021 [111]Female
Afib, HF, pacemaker, asthma		76AAC onset: dry cough and dyspnea simultaneously

Acute hypoxic respiratory failure due
to COVID-19 pneumonia—oxygen via nasal cannula		Right upper quadrant abdominal pain, nausea, vomiting, positive Murphy’s sign. Ultrasound: increased gallbladder
wall thickness with mild pericholecystic fluid collection.		Conservatively—remdesivir, vitamin supplements, piperacillin/tazobactam, dexamethasone, apixaban. Scheduled for elective cholecystectomy.Recovered
Hassani, 2020 [112]Male
artHTN, IHD-CABG		65AAC onset: abrupt with abdominal pain

COVID-19 pneumonia—ambulatory		Abdominal pain, intermittent shaking chills without fever, positive Murphy’s sign, vomiting. Ultrasound: increased gallbladder wall thickness.Conservatively—favipiravir, intravenous crystalloid resuscitation, analgesics.Recovered
Alhassan, 2020 [91]Female40AAC onset: after 2 days of high-grade fever,
generalized body aches, nausea, and moderate right hypochondrium
pain

COVID-19 pneumonia—ambulatory		Fever,
generalized body aches, nausea, moderate right hypochondrium
pain, positive Murphy’s sign. Ultrasound: thickened gall bladder wall, surrounding
pericholecystic fluid, and minimal free fluid in the abdomen and the
pelvis.		Conservatively.

Antibiotics.		Recovered
Safari, 2020 [113]Female
chronic kidney disease,
valvular heart disease,
hypertension		75AAC onset: not defined

COVID-19 positive—only cough—ambulatory		CT scan: acute cholecystitis—gallbladder empyema.Unsuccessful nonoperative management for 48 h;
she was scheduled for laparoscopic cholecystectomy		Death
Basukala, 2021 [114]Male
DM		47AAC onset: after 6 days in COVID-19 ward

COVID-19 positive—fever, cough, dyspnea—ambulatory		Right
upper abdominal pain; positive Murphy’s sign was present. Initial ultrasound: acute cholecystitis.		Initial conservative management failed. Patient developed gallbladder perforation.
Emergency exploratory laparotomy and cholecystectomy.
Histopathological
report revealed gallbladder perforation at the fundus upon gross examination
and ischemic necrosis of gallbladder mucosa upon microscopic
examination.		Recovered
ICU-associated COVID-19 AAC
Puig, 2021 [20]Male
ex-smoker, ArtHTN		65AAC: 7 days after extubation

10 days fever—ARDS due to COVID-19—NIMV—intubation—extubation after 5 days—HFNC—reintubation due to septic shock—extubation and HFNC—re-intubation due to lower gastrointestinal bleeding—tracheotomy—weaning		Tachypnea together with intense abdominal pain with guarding in the right upper quadrant, septic shock, massive bilateral pulmonary embolism, ischemic colitis. CT scan.Ultrasound-guided percutaneous cholecystostomy, ertapenem, enoxaparinRecovered
Franch-Llasat, 2022 [103]Male73AAC onset: after 2 days in ward, following 41 days in the ICU

ARDS due to COVID-19—intubation—mechanical ventilation for 34 days—enteral nutrition for 41 days—extubated		Two days after ICU discharge: abdominal pain, fever, elevated CRP. Ultrasound: hydropic gallbladder with thickened walls and incipient necrosis.Due to the patient’s frail condition, percutaneous drainage was performed, and antibiotics were administered.Recovered
Franch-Llasat, 2022 [103]Male42AAC onset: after 2 days in a rehabilitation center, following 36 days in the ICU

ARDS due to COVID-19—intubation—mechanical ventilation for 35 days—enteral nutrition for 36 days—extubated		Twelve days after extubation: persistent abdominal pain. CT scan: distended gallbladder with poorly defined walls suggestive of edema.Laparoscopic cholecystectomy, antibiotics. Staphylococcus warneri was isolated in the bile.Recovered
Franch-Llasat, 2022 [103]Male67AAC onset: after 20 days in a rehabilitation center, following 70 days in the ICU

ARDS due to COVID-19—intubation—mechanical ventilation for 63 days—enteral nutrition for 70 days—extubated		Twenty days after extubation: abdominal pain, vomiting, leukocytosis. Ultrasound: distended gallbladder with an edematous wall.Laparoscopic cholecystectomy, antibiotics, emergency reoperation for hemorrhagic shock secondary to bleeding from the cystic arteryRecovered
Deif, 2022 [105]Male
IHD. AKI		72AAC onset: after mechanical ventilation for 40 days

COVID-19 pneumonia		Fever. Ultrasound: acute
cholecystitis, distended thick-walled gall bladder with biliary dilatation.		Percutaneous cholecystostomyDeath
Deif, 2022 [105]Male
Jaundice. AKI (on
dialysis)		61AAC onset: after mechanical ventilation for 2 days

COVID-19 pneumonia		Fever. Ultrasound: cholangitis and
cholecystitis.		Percutaneous cholecystostomyDeath
Wahid, 2020 [106]Female
artHTN, DM2, hypothyroidism		60AAC onset: after 44 days of hospitalization including mechanical ventilation

ARDS due to COVID-19 pneumonia		Fever, positive Murphy’s sign. Ultrasound and CT scan: gallbladder distension, biliary sludge.Cholecystostomy tube and
antibiotics		Recovered
Wahid, 2020 [106]Male68AAC onset: after 67 days of hospitalization including mechanical ventilation

ARDS due to COVID-19 pneumonia		Positive Murphy’s sign. Ultrasound and CT scan: gallbladder distension, biliary sludge.Cholecystostomy tube and
antibiotics		Recovered
Chen, 2022 [116]F: 3 (33%)
M: 6 (67%)
9 cases vs. 203 controls		60 (52, 68)AAC onset: not defined

Mechanical ventilation: 8 (89%)		Ultrasound
severity: not defined.		Percutaneous cholecystostomyDeath: 5 (56%)
Recovered: 4 (44%)
Mattone, 2020 [21]Male
ex-smoker		66AAC onset: 49 days after intubation in ICU

ARDS due to COVID-19 pneumonia—intubated		At 49th day of hospitalization: right upper quadrant abdominal pain, nausea, vomiting, tender abdomen, positive Murphy’s sign.
CT scan: gallbladder wall thickening, no gallstones.		A percutaneous transhepatic biliary drainage (PTBD) under ultrasound
control of gallbladder. A sample of bile
was tested for SARS-CoV-2 RNA, and it was negative.
Laparoscopic cholecystectomy after 3 days with no improvement.		Recovered
Bruni, 2020 [95]Male59AAC onset: after 32 days in ICU

ARDS due to COVID-19—intubated—mechanical ventilation for 8 days		At 32nd day of hospitalization: abdominal pain
without signs of peritonism, increased inflammatory and cholestasis indexes.
CT scan: gallbladder perforation.		Laparotomic cholecystectomyRecovered
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Thomaidou, E.; Karlafti, E.; Didagelos, M.; Megari, K.; Argiriadou, E.; Akinosoglou, K.; Paramythiotis, D.; Savopoulos, C. Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review. Viruses 2024, 16, 455. https://doi.org/10.3390/v16030455

AMA Style

Thomaidou E, Karlafti E, Didagelos M, Megari K, Argiriadou E, Akinosoglou K, Paramythiotis D, Savopoulos C. Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review. Viruses. 2024; 16(3):455. https://doi.org/10.3390/v16030455

Chicago/Turabian Style

Thomaidou, Evanthia, Eleni Karlafti, Matthaios Didagelos, Kalliopi Megari, Eleni Argiriadou, Karolina Akinosoglou, Daniel Paramythiotis, and Christos Savopoulos. 2024. "Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review" Viruses 16, no. 3: 455. https://doi.org/10.3390/v16030455

APA Style

Thomaidou, E., Karlafti, E., Didagelos, M., Megari, K., Argiriadou, E., Akinosoglou, K., Paramythiotis, D., & Savopoulos, C. (2024). Acalculous Cholecystitis in COVID-19 Patients: A Narrative Review. Viruses, 16(3), 455. https://doi.org/10.3390/v16030455

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop